Stage 4 pancreatic cancer, also called metastatic pancreatic cancer, occurs when cancer cells spread beyond the pancreas to distant organs including the liver, lungs, or peritoneum, requiring comprehensive treatment strategies that balance life extension with quality of life preservation. TL;DR Only 15-20% of pancreatic cancers are diagnosed at potentially resectable stages, with most patients presenting with stage 4 disease requiring systemic therapy [1] FOLFIRINOX achieved

TL;DR Stage 4 pancreatic cancer treatment focuses on controlling disease progression, managing symptoms, and maintaining quality of life rather than cure, with median survival of 11 months for FOLFIRINOX and 8.5 months for gemcitabine-based regimens [1] Dr. Bharat Patodiya provides personalized stage 4 treatment protocols combining chemotherapy, targeted therapy, and comprehensive supportive care through multidisciplinary coordination Only 49.1% of stage 4 pancreatic cancer p

TL;DR FOLFIRINOX chemotherapy extends median overall survival to 11 months in metastatic pancreatic cancer, compared to 8.5 months with gemcitabine plus nab-paclitaxel-based regimens [1] Only 49.1% of stage IV pancreatic cancer patients receive systemic therapy, with significant disparities based on age, insurance status, and treatment facility type [2] Dr.Bh arat Patodiya's multidisciplinary approach integrates medical oncology, surgical consultation, and personalized treat